Ifp Advisors, Inc Uni Qure N.V. Transaction History

Ifp Advisors, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$18.12 - $27.32 $2,917 - $4,398	-161 Reduced 61.69%	100 $4,000
Q2 2022 Sep 06, 2022	BUY	$13.15 - $20.45 $3,432 - $5,337	261 New	261 $22,000
Q2 2022 Aug 12, 2022	SELL	$13.15 - $20.45 $3,432 - $5,337	-261 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$14.54 - $21.5 $2,340 - $3,461	161 Added 161.0%	261 $4,000
Q1 2021 Apr 30, 2021	SELL	$29.24 - $42.03 $1,257 - $1,807	-43 Reduced 30.07%	100 $3,000
Q3 2020 Oct 29, 2020	BUY	$35.98 - $47.66 $1,547 - $2,049	43 Added 43.0%	143 $5,000
Q2 2020 Aug 05, 2020	SELL	$45.06 - $67.74 $2,072 - $3,116	-46 Reduced 31.51%	100 $5,000
Q4 2019 Jan 17, 2020	BUY	$37.13 - $74.62 $1,707 - $3,432	46 Added 46.0%	146 $11,000
Q3 2019 Nov 07, 2019	BUY	$39.36 - $76.8 $3,936 - $7,680	100 New	100 $4,000
Q1 2019 May 15, 2019	SELL	$27.39 - $68.41 $2,739 - $6,841	-100 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$29.75 - $43.08 $2,975 - $4,308	100 New	100 $0

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $273M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.